Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3142 Target Snapshot

DNA-dependent protein kinase catalytic subunit · SINGLE PROTEIN · Homo sapiens

2,255Compounds
325Assays
3Approved Drugs
3,171.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P78527. Start with chronic lymphocytic leukemia, then reuse UniProt P78527 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic lymphocytic leukemia, then reuse UniProt P78527 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
chronic lymphocytic leukemia

DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include CC-115. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DNA-dependent protein kinase catalytic subunit as ChEMBL target CHEMBL3142, mapped to UniProt P78527. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DNA-dependent protein kinase catalytic subunit
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3142
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P78527
DNA-dependent protein kinase catalytic subunit
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether DNA-dependent protein kinase catalytic subunit is the right protein anchor across sources, using UniProt P78527 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDNA-dependent protein kinase catalytic subunit
UniProt AccessionP78527
Component TypeProtein
Sequence Length4128 aa

DNA-dependent protein kinase catalytic subunit

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as DNA-dependent protein kinase catalytic subunit, mapped to UniProt P78527. Sequence length is 4128 aa.

Mapped IDP78527
Review nameDNA-dependent protein kinase catalytic subunit
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

DNA-dependent protein kinase catalytic subunit shows clinical signal disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.

Clinical signal Phase I
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugCC-115
Clinical signal Phase I
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugCC-115
Clinical signal Phase I
head and neck squamous cell carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCC-115
Clinical signal Phase I
metastasis
1 linked drug · 1 direct · 1 efficacy
Linked drugCC-115
Clinical signal Phase I
osteosarcoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCC-115
Clinical signal Phase I
prostate cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugCC-115
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with chronic lymphocytic leukemia because it currently carries clinical signal support. Linked drugs include CC-115. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic lymphocytic leukemia
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
5
Phase III
13
Phase II
5
Phase I
Assay Mix

Activity Type Distribution

IC503,091.0
KI65.0
EC506.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4447991 10.1 IC50 0.07943 Preclinical
CHEMBL5563688 10.0 IC50 0.1 Preclinical
CHEMBL5566630 10.0 IC50 0.1 Preclinical
CHEMBL5570653 9.96 IC50 0.11 Preclinical
CHEMBL5180090 9.92 IC50 0.12 Preclinical
CHEMBL5194436 9.89 IC50 0.13 Preclinical
CHEMBL6065576 9.8 IC50 0.158 Preclinical
CHEMBL5890243 9.8 IC50 0.158 Preclinical
CHEMBL4560221 9.8 IC50 0.158 Preclinical
CHEMBL4450232 9.7 IC50 0.1995 Preclinical
Distribution

pChEMBL Value Distribution

212
5.0
219
5.5
213
6.0
197
6.5
106
7.0
506
7.5
507
8.0
31
8.5
47
9.0
47
9.5
pChEMBL
Approved Drugs

Approved Drugs

LENIOLISIB
CHEMBL3643413
Approved 2023
Assay Landscape

Assay Landscape

325
Total Assays
1,455
Tested Compounds
1
Assay Types
Binding — 325 assays, 1,455 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 201 1,262 7.2
cell-based format 86 179 6.3
subcellular format 28 4 7.2
assay format 10 10 7.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine